



IFW 1624 JS

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)		Application Number	09/941897-Conf. #7824
		Filing Date	August 28, 2001
		First Named Inventor	James W. Halbrook
		Art Unit	1624
		Examiner Name	B. Kifle
Total Number of Pages in This Submission	6	Attorney Docket Number	N0260.70067US01

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input checked="" type="checkbox"/> Other Enclosure(s) (please Identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	References cited
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> CD, Number of CD(s) _____	Return Receipt Postcard
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Landscape Table on CD	Check for \$180.
<input type="checkbox"/> Reply to Missing Parts/Incomplete Application	Remarks The Director may charge our account 23/2825 for any deficiencies associated with this filing.	
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	WOLF, GREENFIELD & SACKS, P.C.		
Signature			
Printed name	Roque El-Hayek		
Date	March <u>21</u> , 2006	Reg. No.	55,151

Certificate of Mailing Under 37 CFR 1.8(a)

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: March 21, 2006

Signature: (Sheila Gravina)



DOCKET NO.: N0260.70067US01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: James Halbrook, et al.
Serial No.: 09/941,897
Confirmation No.: 7824
Filed: August 28, 2001
For: MATERIALS AND METHODS TO POTENTIATE
CANCER TREATMENT
Examiner: Kifle, Bruck
Art Unit: 1624

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to MAIL STOP AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 21st day of March, 2006.


Sheila Gravina

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**STATEMENT FILED PURSUANT TO THE DUTY OF
DISCLOSURE UNDER 37 CFR §§1.56, 1.97 AND 1.98**

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, the Applicant requests consideration of this Information Disclosure Statement.

PART I: Compliance with 37 C.F.R. §1.97

This Information Disclosure Statement has been filed after the mailing date of the first Office Action after the filing date of the request for continued examination of this application under 37 C.F.R. §1.114, but before the mailing date of either a final action under 37 C.F.R. §1.113 or a Notice of Allowance under 37 C.F.R. §1.311, or an action that otherwise closes prosecution in this application.

The fee of \$180.00 as set forth in 37 C.F.R. §1.17(p) is enclosed.

03/29/2006 YPOLITE1 00000082 09941897

01 FC:1806

180.00 0P

PART II: Information Cited

The Applicant hereby makes of record in the above-identified application the information listed on the attached form PTO-1449 (modified). The order of presentation of the references should not be construed as an indication of the importance of the references.

The Applicant hereby makes the following additional information of record in the above-identified application.

The Applicant would like to bring to the Examiner's attention the following pending applications that may contain subject matter related to this application:

<u>Serial No.</u>	<u>Filing Date</u>	<u>Inventor(s)</u>
10/550978	September 26, 2005	Halbrook et al.

PART III: Remarks

Documents cited anywhere in the Information Disclosure Statement are enclosed unless otherwise indicated. It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
2. The enclosed form PTO-1449 be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;
3. The citations for the information be printed on any patent which issues from this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

Serial No.: 09/941,897
Conf. No.: 7824

- 3 -

Art Unit: 1624


By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his own conclusion regarding the relevance of the cited information.

An early and favorable action is hereby requested.

Respectfully submitted,
James Halbrook, et al., Applicants

By:



Roque El-Hayek, Reg. No. 55,151
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210-2206
Telephone: (617) 646-8000

Docket No.: N0260.70067US01
Date: March 21, 2006



FORM PTO-1449 (Rev. 11-2003) (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT			APPLICATION NO.: 09/941,897		ATTY. DOCKET NO.: N0260.70067US01	
			FILING DATE: August 28, 2001		CONFIRMATION NO.: 7824	
			APPLICANT: James Halbrook, et al.			
			GROUP ART UNIT: 1624		EXAMINER: Kifle, Bruck	
Sheet	1	of	2			

U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
	A1	3,904,631		Elslager et al.	09-09-1975
	A2	4,539,412		Archer	09-03-1985
	A3	4,558,043		Wenk et al.	12-10-1985
	A4	6,555,593	B1	Hoyle et al.	04-29-2003
	A5	2001/0027210	A1	Wilson	10-04-2001

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			
	B1	DE	31 41 970	A1	VSESOJUZYNYJ NAUCNO- ISSLEDOVATEL'SKIJ INSTITUT LEKARSTVENNYCH RASTENIJ	05-05-1983	N
	B2	EP	0 471 516	A1	IMPERIAL CHEMICAL INDUSTRIES PLC	02-19-1992	Y
	B3	JP	11-199565		TOYAMA CHEM. CO. LTD	07-27-1999	Abstract only
	B4	WO	02/20500	A2	ICOS CORPORATION	03-14-2002	Y
	B5	WO	01/17985	A1	INDENA S.P.A.	03-15-2001	Y
	B6	WO	96/16632	A1	LABORATOIRES DE BIOLOGIE VEGETALE YVES ROCHER	06-06-1996	Abstract only
	B7	WO	92/16517	A1	XENOVA LIMITED	10-01-1992	Y
	B8	WO	90/14008	A1	SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH	11-29-1990	Y
	B9	WO	96/22077	A1	HENKEL KOMMANDITGESELLSCHAFT AUF	07-25-1996	Abstract only
	B10	WO	99/39247	A1	FIRST CHEMICAL CORPORATION	08-05-1999	Y

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)	
	C1	ABADI, A.H., et al., "Synthesis, Antitumor and Antitubercular Evaluation of Certain New Xanthenone and Acridinone Analogs," <i>Arzneim.-Forsch./Drug Res.</i> 49 (I), Nr. 3, pp. 259-266 (1999)		
	C2	AGASIMUNDIN, Y.S., et al., "Furano compounds. XX. Synthesis of angular and linear furoxanthenes," <i>Journal fuer Praktische Chemie</i> (Leipzig) (1972), 314(3-4), pp. 507-514	Abstract	
	C3	CROISY-DELCEY, M., et al., "Aza Analogues of Lucanthon: Synthesis and Antitumor and Bactericidal Properties," <i>J. Med. Chem.</i> (1983), 26, pp. 1329-1333		
	C4	FONTENEAU, N., et al., "Synthesis of quinone and xanthone analogs of rhein," <i>Tetrahedron</i> 57 (2001) pp. 9131-9135		
	C5	FUJIOKA, H., et al., "Activities of New Acridone Alkaloid Derivatives against Plasmodium yoelii		

FORM PTO-1449/A and B (Modified)		APPLICATION NO.: 09/941,897	ATTY. DOCKET NO.: N0260.70067US01
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		FILING DATE: August 28, 2001	CONFIRMATION NO.: 7824
		APPLICANT: James Halbrook, et al.	
		GROUP ART UNIT: 1624	EXAMINER: Kifle, Bruck
Sheet	2	of	2

OTHER ART — NON PATENT LITERATURE DOCUMENTS (continued)

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
		in vitro," <i>Arzneim.-Forsch./Drug Res.</i> 40 (II), Nr. 9 (1990), pp. 1026-1029	
	C6	GHOSH, C.K., et al., "Benzopyrans. Part 30. Synthesis of Substituted Xanthenes from 3-Acyl-2-methyl-1-benzopyran-4-ones," <i>Tetrahedron</i> Vol. 49, No. 19, pp. 4127-4134, 1993	
	C7	GOUD, A.N., et al., "Furan compounds. XVI," <i>Monatsh. Chem.</i> (1969), 100(1), pp. 38-41	Abstract
	C8	HARFENIST, M., et al., "Selective Inhibitors of Monoamine Oxidase. 3. Structure-Activity Relationship of Tricyclics Bearing Imidazoline, Oxadiazole, or Tetrazole Groups," <i>J. Med. Chem.</i> 1996, 39, pp. 1857-1863	
	C9	KLOPMAN, G., et al., "An artificial intelligence approach to the study of the structural moieties relevant to drug-receptor interactions in aldose reductase inhibitors," <i>Molecular Pharmacology</i> (1988), 34(6), pp. 852-862	Abstract
	C10	MARI, S., et al., "Flavone and xanthone derivatives related to fluoroquinolones," <i>Il Farmaco</i> 54 (1999) pp. 411-415	
	C11	TABARRINI, O., et al., "Design and Synthesis of Modified Quinolones as Antitumoral Acridones," <i>J. Med. Chem.</i> , 1999, Vol. 42, No. 12, pp. 2136-2144	
	C12	XUAN, T., et al., "Two new O- and C-glycosylxanthenes from the <i>Gentiana tizuensis</i> Franch," <i>Gaodeng Xuexiao Huaxue Xuebao</i> (2001), 22(10, Suppl.), pp. 148-150	Abstract

EXAMINER:	DATE CONSIDERED:
-----------	------------------

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __, filed __, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - The Office hereby waives the requirement under 37 CFR 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b). For all patent applications filed on or before June 30, 2003, copies of cited U.S. patents and patent application publications are still required unless an IDS is filed. Copies of all other patent(s), publication(s), or other information listed must still be provided, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]